Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy
2011

Periostin as a Target for Prostate Cancer Treatment

Sample size: 116 publication 10 minutes Evidence: moderate

Author Information

Author(s): Sun Chuanyu, Zhao Xiaojun, Xu Ke, Gong Jian, Liu Weiwei, Ding Weihong, Gou Yuancheng, Xia Guowei, Ding Qiang

Primary Institution: Huashan Hospital, Fudan University

Hypothesis

Silencing Periostin by RNA interference will affect the proliferation and migration of prostate cancer cells.

Conclusion

Silencing Periostin can inhibit the proliferation and migration of prostate cancer cells, suggesting it may be a promising therapeutic target.

Supporting Evidence

  • Periostin was found to be 9.12 times more expressed in prostate cancer compared to benign prostate hyperplasia.
  • Silencing Periostin led to a significant decrease in cell proliferation and migration.
  • The study confirmed Periostin's expression in prostate cancer tissues through immunohistochemical staining.

Takeaway

This study found that a protein called Periostin helps prostate cancer cells grow and move. By turning off this protein, we can slow down the cancer.

Methodology

The study used proteomics analysis, RNA interference, and various assays to evaluate Periostin's role in prostate cancer.

Potential Biases

Potential bias in sample selection and the focus on a single cell line.

Limitations

The study primarily focused on one cell line and may not represent all prostate cancer types.

Participant Demographics

Patients with prostate cancer and benign prostate hyperplasia.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1477-5956-9-22

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication